Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/68520
Type
ArticleCopyright
Restricted access
Embargo date
3100-12-31
Collections
Metadata
Show full item record
HELMINTHIASIS AND MPOX VACCINATION: CHALLENGES IN SUB-SAHARAN AFRICA.
Affilliation
Department of Public Health and Infectious Diseases. University of Rome Sapienza. Rome, Italy. / Azienda Ospedaliero Universitaria Umberto I. Rome, Italy. / Migrant and Global Health Research Organization. Mi-Hero, Italy.
Unit of Medical Statistics and Molecular Epidemiology. University Campus Bio-Medico of Rome. Rome, Italy.
Department of Biomedical Sciences. University of Sassari. Sassari, Italy.
Doenças Amplificadas pelo Clima e Epidemias. Belo Horizonte, MG, Brasil. / Fundação Oswaldo Cruz. Instituto Rene Rachou. Belo Horizonte, MG, Brasil. / Sciences and Technologies for Sustainable Development and One Health. Università Campus Bio-Medico di Roma. Rome, Italy.
Migrant and Global Health Research Organization. Mi-Hero, Italy. / Unit of Medical Statistics and Molecular Epidemiology. University Campus Bio-Medico of Rome. Rome, Italy.
Unit of Medical Statistics and Molecular Epidemiology. University Campus Bio-Medico of Rome. Rome, Italy.
Department of Biomedical Sciences. University of Sassari. Sassari, Italy.
Doenças Amplificadas pelo Clima e Epidemias. Belo Horizonte, MG, Brasil. / Fundação Oswaldo Cruz. Instituto Rene Rachou. Belo Horizonte, MG, Brasil. / Sciences and Technologies for Sustainable Development and One Health. Università Campus Bio-Medico di Roma. Rome, Italy.
Migrant and Global Health Research Organization. Mi-Hero, Italy. / Unit of Medical Statistics and Molecular Epidemiology. University Campus Bio-Medico of Rome. Rome, Italy.
xmlui.dri2xhtml.METS-1.0.item-abstractes
The ongoing mpox outbreak in sub-Saharan Africa has highlighted the critical need for equitable vaccine access and robust logistical support. However, these factors alone are insufficient to ensure the success of vaccination campaigns in regions characterized by unique epidemiological and immunological challenges. One significant issue is the high prevalence of helminth infections, which are known to impair immune responses to vaccines, potentially reducing both short-term efficacy and long-term antibody titers. This paper explores the implications of helminthiasis for mpox vaccination in sub-Saharan Africa, emphasizing the need for integrated strategies to address this co-infection. We discuss whether combining deworming programs with vaccination campaigns could enhance vaccine responses and examine the applicability of emerging data on single-dose mpox vaccination in the context of endemic helminth infections. Furthermore, we highlight the importance of real-time surveillance to monitor vaccine effectiveness and identify breakthrough infections in regions with high helminth prevalence. Our findings underscore the necessity of a context-specific approach to mpox vaccination policies, one that considers the intricate interplay between helminth infections and vaccine efficacy. Addressing these challenges is essential to ensure the success of vaccination efforts and to mitigate the broader public health impact of mpox in Africa and beyond.
Share